Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T22:20:39.281Z.
Calculation as of: 2026-10-06T22:20:39.281Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8d554412806125b06490580232e6d80b3120c6a72214b764814008bb1d876b03
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Ainos, Inc.
Market Cap
$9.50M
Price/FCF Ratio
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO |
|---|---|---|
| Ainos, Inc. (AIMD) | $9.50M | N/A |
| Satellos Bioscience Inc. (MSLE)vs › | $9.71M | N/A |
| MetaVia Inc. (MTVA)vs › | $9.75M | N/A |
| NeuroOne Medical Technologies Corporation (NMTC)vs › | $9.83M | N/A |
| Valion Bio, Inc. (VBIO)vs › | $9.86M | N/A |
| Jasper Therapeutics, Inc. (JSPR)vs › | $9.10M | N/A |
| SeaStar Medical Holding Corporation (ICU)vs › | $9.05M | N/A |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.06M | N/A |
| Senti Biosciences, Inc. (SNTI)vs › | $10.06M | N/A |
| Tvardi Therapeutics, Inc. (TVRD)vs › | $10.13M | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
